GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS

The article represents the results of efficacy and safety evaluation of the human monoclonal antibodies — golimumab, according to the data of international multicenter randomized double-blind placebo-controlled trials, including patients with active stage of rheumatoid arthritis. It was shown, that...

Full description

Bibliographic Details
Main Authors:	R. V. Denisova, E. I. Alexeeva
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2012-07-01
Series:	Voprosy Sovremennoj Pediatrii
Subjects:	golimumab rheumatoid arthritis juvenile idiopathic arthritis
Online Access:	https://vsp.spr-journal.ru/jour/article/view/449

id	doaj-435068862d364df0b9a956a8b24ed570
record_format	Article
spelling	doaj-435068862d364df0b9a956a8b24ed5702021-07-28T21:15:29Zeng"Paediatrician" Publishers LLC Voprosy Sovremennoj Pediatrii1682-55271682-55352012-07-01114142010.15690/vsp.v11i4.354449GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTSR. V. Denisova0E. I. Alexeeva1Scientific Centre of Children Health, RAMS, MoscowScientific Centre of Children Health, RAMS, Moscow I.M. Setchenov First Moscow State Medical UniversityThe article represents the results of efficacy and safety evaluation of the human monoclonal antibodies — golimumab, according to the data of international multicenter randomized double-blind placebo-controlled trials, including patients with active stage of rheumatoid arthritis. It was shown, that golimumab was reliably more effective than placebo both when administered hypodermic and intravenous. The safety profile of golimumab is comparable to that of the other tumor necrosis factor alpha blockers. The review also contains information on the 3d phase of golimumab efficacy and safety research in patients with juvenile idiopathic arthritis.https://vsp.spr-journal.ru/jour/article/view/449golimumabrheumatoid arthritisjuvenile idiopathic arthritis
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	R. V. Denisova E. I. Alexeeva
spellingShingle	R. V. Denisova E. I. Alexeeva GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS Voprosy Sovremennoj Pediatrii golimumab rheumatoid arthritis juvenile idiopathic arthritis
author_facet	R. V. Denisova E. I. Alexeeva
author_sort	R. V. Denisova
title	GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS
title_short	GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS
title_full	GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS
title_fullStr	GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS
title_full_unstemmed	GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS
title_sort	golimumab — a new tnf α-blocker. the review of the efficacy and safety evaluation results
publisher	"Paediatrician" Publishers LLC
series	Voprosy Sovremennoj Pediatrii
issn	1682-5527 1682-5535
publishDate	2012-07-01
description	The article represents the results of efficacy and safety evaluation of the human monoclonal antibodies — golimumab, according to the data of international multicenter randomized double-blind placebo-controlled trials, including patients with active stage of rheumatoid arthritis. It was shown, that golimumab was reliably more effective than placebo both when administered hypodermic and intravenous. The safety profile of golimumab is comparable to that of the other tumor necrosis factor alpha blockers. The review also contains information on the 3d phase of golimumab efficacy and safety research in patients with juvenile idiopathic arthritis.
topic	golimumab rheumatoid arthritis juvenile idiopathic arthritis
url	https://vsp.spr-journal.ru/jour/article/view/449
work_keys_str_mv	AT rvdenisova golimumabanewtnfablockerthereviewoftheefficacyandsafetyevaluationresults AT eialexeeva golimumabanewtnfablockerthereviewoftheefficacyandsafetyevaluationresults
_version_	1721261799316127744

GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS

Similar Items